EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Secondary primary malignancies in indolent non‐Hodgkin lymphoma patients receiving frontline bendamustine‐rituximab

Gwynivere A Davies iD, Anca Prica, Zharmaine Ante, Ning Liu, Gregory R Pond, Amaris K Balitsky iD, Adam Suleman, Lee Mozessohn iD

Cancer · 01.03.2026 · 132 (5)

DOI: 10.1002/cncr.70327 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, online erschienen am 03.03.2026. Verfasst von Gwynivere A Davies und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, McMaster University, Hamilton, Ontario, Canada. Hauptthemen laut MEDLINE: Bendamustine Hydrochloride, Rituximab, Antineoplastic Combined Chemotherapy Protocols, Neoplasms, Second Primary. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Juravinski Hospital & Cancer Centre Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bendamustine‐rituximab (BR) is common frontline therapy for indolent B‐cell non‐Hodgkin lymphomas (iBCL), but its association with secondary primary malignancies (SPM) is unclear.

Methods

The authors conducted a population‐based study using linked Ontario health care databases. Patients ≥18 years old with untreated iBCL receiving BR (2013–2022) were compared to a historical cohort receiving cyclophosphamide‐based regimens (rituximab, cyclophosphamide, vincristine, prednisone/rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone [R‐CVP/CHOP], 2006–2012). Five‐year SPM incidence was assessed using cumulative incidence function and competing risk models. Landmark analysis was conducted at 6 months after index date.

Results

A total of 6878 patients (BR, 4611; R‐CVP/CHOP, 2267) were identified; BR recipients were older (65.6 vs. 62.8 years, p < .001). The 5‐year cumulative incidence of SPM was higher with BR versus R‐CVP/CHOP (8.9% vs. 7.2%, p = .019) as was the SPM rate at 6.4 versus 4.9 per 100,000 person‐days ( p = .006), with higher rates of respiratory tract, male genitourinary, and skin cancers. Myelodysplastic syndrome/acute myeloid leukemia cases were similar accounting for group size ( n = 23 vs. 11, p = .20). Multivariable analysis showed no significant difference in SPM risk (hazard ratio [HR], 1.13; 95% CI, 0.93–1.36, p = .22); full versus abbreviated BR was associated with borderline higher SPM risk (cumulative incidence function, 10.7% vs. 7.2%; HR, 1.51, p = .06). No difference was seen by cycles for R‐CVP/CHOP. Development of SPM shortened survival (HR, 3.67; 95% CI, 3.15–4.29, p < .001).

Conclusions

Although BR patients demonstrated a higher SPM risk at 5 years in univariate models, this finding was not present on multivariable analysis. An increased number of BR cycles was associated with borderline increased SPM risk. These findings require prospective validation and studies examining risk‐adapted abbreviation of chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bendamustine HydrochlorideRituximabAntineoplastic Combined Chemotherapy ProtocolsNeoplasms, Second PrimaryLymphoma, Non-HodgkinLymphoma, B-CellHumansMiddle AgedMaleFemaleAgedVincristineCyclophosphamidePrednisoneDoxorubicinIncidenceAdultOntarioAged, 80 and over

Stichwörter der Autor:innen

Ontariobendamustinecounselingdelivery of health carelymphomaneoplasmnon‐Hodgkinrituximab

Substanzen

Bendamustine HydrochlorideRituximabVincristineCyclophosphamidePrednisoneDoxorubicinR-CVP protocol

Autor:innen und Institutionen

  • Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
  • Hamilton Health Sciences, Juravinski Cancer Center, Hamilton, Ontario, Canada.
  • Escarpment Cancer Research Institute, Hamilton, Ontario, Canada.
  • Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
  • Cancer Research Program, ICES, Toronto, Ontario, Canada.

ORCID-Profile: Gwynivere A Davies, Amaris K Balitsky, Lee Mozessohn

Förderung

  • Juravinski Hospital & Cancer Centre Foundation

Zitieren

APA

Davies, G. A., Prica, A., Ante, Z., Liu, N., Pond, G. R., Balitsky, A. K., Suleman, A., & Mozessohn, L. (2026). Secondary primary malignancies in indolent non‐Hodgkin lymphoma patients receiving frontline bendamustine‐rituximab. Cancer, 132(5). https://doi.org/10.1002/cncr.70327

Vancouver

Davies GA, Prica A, Ante Z, Liu N, Pond GR, Balitsky AK, et al. Secondary primary malignancies in indolent non‐Hodgkin lymphoma patients receiving frontline bendamustine‐rituximab. Cancer. 2026;132(5). doi:10.1002/cncr.70327

BibTeX
@article{Davies2026,
  author = {Davies, Gwynivere A and Prica, Anca and Ante, Zharmaine and Liu, Ning and Pond, Gregory R and Balitsky, Amaris K and Suleman, Adam and Mozessohn, Lee},
  title = {Secondary primary malignancies in indolent non‐Hodgkin lymphoma patients receiving frontline bendamustine‐rituximab},
  journal = {Cancer},
  year = {2026},
  volume = {132},
  number = {5},
  doi = {10.1002/cncr.70327}
}
Kostenlos starten →